Fingerprint
Dive into the research topics of 'A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically